The European Medicines Agency (EMA) recommends extension of indications for daratumumabAccess, Myeloma21 October 2019
European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myelomaAccess, Myeloma28 August 2019
Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)Access, Myeloma19 July 2019
Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosisAccess, AL amyloidosis6 June 2019
Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, Myeloma23 May 2019
Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on accessAccess, MPE6 May 2019
Huge variations between countries in time for reimbursement decisions on new cancer drugsAccess20 October 2018
Delays in access to new cancer medicines and unjustifiable price rises for old ones disadvantage patients unnecessarilyAccess28 January 2017
EMA reconsiders and gives its positive opinion for the approval of ixazomibAccess, Myeloma17 September 2016
